Glucagon-like peptide-1 based therapies as a novel approach for chronic heart failure

David Grieve, Emma Robinson, Mitchel Tate, Brian Green, Barbara McDermott

Research output: Contribution to conferenceAbstractpeer-review

Abstract

Glucagon-like peptide-1 (GLP-1) is an endogenous peptide hormone whose metabolic effects have been exploited for glycaemic control in diabetes, but which also exerts important cardiovascular actions. We have recently reported that the GLP-1 mimetic, exendin-4, exerts clear benefits post-myocardial infarction via specific effects on extracellular matrix remodelling which is dysregulated in the diabetic heart (Robinson E et al, Basic Res Cardiol 2015; 110: 20), and have now shown similar cardioprotective actions in experimental diabetes, which are mediated via direct effects on infiltrating macrophages (Tate M et al, Basic Res Cardiol 2015; in press). Taken together with the apparent complexity of GLP-1 signalling and disappointing results of recent cardiovascular trials, our work strongly suggests that selective targeting of GLP-1 may be required in order to realise therapeutic benefit for both diabetic and non-diabetic heart failure patients. This is particularly important given the epidemic increase in the incidence of diabetes which is associated with a markedly enhanced susceptibility to cardiovascular stress.
Original languageEnglish
Publication statusAccepted - 30 May 2016
Event8th International Congress of Cardiology 2016 - Barcelona, Spain
Duration: 28 May 201630 May 2016

Conference

Conference8th International Congress of Cardiology 2016
CountrySpain
CityBarcelona
Period28/05/201630/05/2016

Fingerprint

Dive into the research topics of 'Glucagon-like peptide-1 based therapies as a novel approach for chronic heart failure'. Together they form a unique fingerprint.

Cite this